Saturday, July 12, 2014 Last update: 12:33 AM
FreshNews.com - All Company Technology News Since 1996

Implant Sciences to Present at the Noble Financial Equity Conference

Companies mentioned in this article: Implant Sciences Corporation

WILMINGTON, MA -- (Marketwire) -- 01/22/13 -- Fresh off the significant news that its Quantum Sniffer™ QS-B220 has been approved by the TSA for air cargo screening, Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that Glenn D. Bolduc, President and Chief Executive Officer, will present at "NINE," Noble Financial Capital Markets' Ninth Annual Equity Conference at the Hard Rock Hotel in Hollywood, Florida, on Tuesday, January 22, 2013 at 4:30 PM Eastern Time. Noble Financial is a research driven, full-service investment banking boutique focused on small-cap emerging growth companies.

At the time of the presentation, a live audio and high-definition video webcast of Implant Sciences' presentation and a copy of the presentation materials will be available on the Company's website, or through the Noble Financial websites: www.noblefcm.com or www.nobleresearch.com/NINE/home.htm. Investors interested in viewing Implant Sciences' presentation may register at least 10 minutes prior to the start of the presentation to ensure timely access. A Microsoft SilverLight viewer (a free download from the presentation link) will be required to participate. The webcast and presentation will also be archived on Implant Sciences' website for 90 days following the event.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine


Contact:

Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact